Piper Jaffray Assumes Horizon Pharma (HZNP) at Overweight (Earlier)

Piper Jaffray assumes coverage on Horizon Pharma (NASDAQ: HZNP) with a Overweight rating and a price target of $22.00.

Analyst avid Amsellem said, "With a 2016 P/E of only 10x, strong visibility on sustainable LT double-digit EPS growth, and ample bandwidth to execute on additional accretive M&A, HZNP is well positioned for further value creation."

For an analyst ratings summary and ratings history on Horizon Pharma click here. For more ratings news on Horizon Pharma click here.

Shares of Horizon Pharma closed at $16.18 yesterday.

You May Also Be Interested In

• KeyBanc Starts Super Micro Computer (SMCI) at Sector Weight, 'shares currently trading relatively inline with its infrastructure peer group'
• Citi Upgrades Sirius XM Radio (SIRI) to Neutral, 'risk-reward is balanced at prevailing levels'
• Citi Downgrades Liberty SiriusXM (LSXMA) to Neutral, 'fairly balanced at prevailing levels'